atha-10q_20210331.htm
false 2021 Q1 0001620463 --12-31 true true true P6Y6M P6Y4M24D P6Y2M1D P6Y10M13D P7Y11M23D P8Y3M7D P9Y4M20D P5Y2M8D 0001620463 2021-01-01 2021-03-31 xbrli:shares 0001620463 2021-05-10 iso4217:USD 0001620463 2021-03-31 0001620463 2020-12-31 iso4217:USD xbrli:shares 0001620463 2020-01-01 2020-03-31 0001620463 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001620463 us-gaap:CommonStockMember 2019-12-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001620463 us-gaap:RetainedEarningsMember 2019-12-31 0001620463 2019-12-31 0001620463 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001620463 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001620463 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0001620463 us-gaap:CommonStockMember 2020-03-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001620463 us-gaap:RetainedEarningsMember 2020-03-31 0001620463 2020-03-31 0001620463 us-gaap:CommonStockMember 2020-12-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001620463 us-gaap:RetainedEarningsMember 2020-12-31 0001620463 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001620463 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001620463 us-gaap:CommonStockMember 2021-03-31 0001620463 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001620463 us-gaap:RetainedEarningsMember 2021-03-31 0001620463 atha:GrantLiabilityMember 2021-01-01 2021-03-31 0001620463 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-01-01 2021-03-31 0001620463 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001620463 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001620463 atha:FollowOnPublicOfferingMember 2021-01-01 2021-01-31 0001620463 us-gaap:OverAllotmentOptionMember 2021-02-01 2021-02-28 0001620463 atha:FollowOnPublicOfferingMember 2021-01-31 0001620463 us-gaap:OverAllotmentOptionMember 2021-02-28 0001620463 atha:AlzheimerSAssociationPartCloudResearchGrantMember 2020-01-01 2020-03-31 0001620463 atha:NationalInstitutesOfHealthGrantMember 2021-01-01 2021-03-31 0001620463 atha:AlzheimerSAssociationPartCloudResearchGrantMember 2020-12-31 0001620463 atha:NationalInstitutesOfHealthGrantMember 2021-03-31 0001620463 atha:NationalInstitutesOfHealthGrantMember 2020-12-31 0001620463 atha:AlzheimersAssociationMember 2019-01-31 0001620463 atha:AlzheimersAssociationMember 2019-01-01 2019-12-31 0001620463 atha:AlzheimersAssociationMember 2021-01-01 2021-03-31 0001620463 atha:NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember 2020-12-01 2020-12-31 0001620463 atha:NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember 2020-12-31 0001620463 us-gaap:AccountingStandardsUpdate201602Member 2021-03-31 0001620463 us-gaap:AccountingStandardsUpdate201807Member 2021-03-31 atha:Segment 0001620463 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 atha:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 atha:LongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member atha:LongTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member atha:LongTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember atha:LongTermInvestmentsMember 2020-12-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember srt:MaximumMember 2021-01-01 2021-03-31 0001620463 us-gaap:FairValueMeasurementsRecurringMember srt:MinimumMember 2021-01-01 2021-03-31 0001620463 atha:GrantLiabilityMember 2021-03-31 0001620463 atha:GrantLiabilityMember 2019-12-31 0001620463 atha:GrantLiabilityMember 2020-01-01 2020-12-31 0001620463 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2019-12-31 0001620463 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2020-01-01 2020-12-31 0001620463 us-gaap:ComputerEquipmentMember 2021-03-31 0001620463 atha:LaboratoryEquipmentMember 2021-03-31 0001620463 atha:LaboratoryEquipmentMember 2020-12-31 0001620463 us-gaap:OfficeEquipmentMember 2021-03-31 0001620463 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001620463 us-gaap:ConstructionInProgressMember 2021-03-31 0001620463 us-gaap:ConstructionInProgressMember 2020-12-31 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember atha:PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember 2020-01-01 2020-12-31 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember atha:PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember 2015-12-31 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember 2015-12-31 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember 2015-01-01 2015-12-31 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember 2021-03-31 0001620463 atha:WashingtonLifeServicesDiscoveryFundGrantAgreementMember 2014-01-01 2014-12-31 0001620463 atha:WashingtonLifeServicesDiscoveryFundGrantAgreementMember 2015-01-01 2015-12-31 0001620463 atha:WashingtonLifeServicesDiscoveryFundGrantAgreementMember 2015-12-31 0001620463 atha:WashingtonLifeServicesDiscoveryFundGrantAgreementMember 2020-09-30 0001620463 atha:WashingtonLifeServicesDiscoveryFundGrantAgreementMember us-gaap:NonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0001620463 atha:UnsecuredConvertibleNotesMember 2021-03-31 0001620463 atha:UnsecuredConvertibleNotesMember 2019-12-31 0001620463 atha:UnsecuredConvertibleNotesMember 2018-12-31 xbrli:pure 0001620463 atha:UnsecuredConvertibleNotesMember 2021-01-01 2021-03-31 0001620463 atha:UnsecuredConvertibleNotesMember 2020-05-01 2020-05-31 0001620463 atha:UnsecuredConvertibleNotesMember 2020-05-31 0001620463 atha:UnsecuredConvertibleNotesMember atha:SeriesB1ConvertiblePreferredStockMember 2020-05-01 2020-05-31 0001620463 atha:LaboratoryAndOfficeFacilitiesMember atha:BothellWashingtonMember 2021-01-01 2021-03-31 0001620463 atha:LaboratoryAndOfficeFacilitiesMember atha:BothellWashingtonMember srt:MinimumMember 2021-03-31 0001620463 atha:LaboratoryAndOfficeFacilitiesMember atha:BothellWashingtonMember srt:MaximumMember 2021-03-31 0001620463 atha:LaboratoryAndOfficeFacilitiesMember atha:BothellWashingtonMember 2021-03-31 0001620463 atha:LaboratoryAndOfficeFacilitiesMember atha:UniversityOfWashingtonSeattleMember 2021-03-31 0001620463 atha:SeriesBConvertiblePreferredStockMember 2020-06-30 0001620463 atha:SeriesBConvertiblePreferredStockMember 2020-05-01 2020-06-30 0001620463 atha:SeriesBConvertiblePreferredStockMember atha:ClassOfWarrantOrRightPurchasePriceOneMember 2020-06-30 0001620463 atha:SeriesB1ConvertiblePreferredStockMember 2020-06-30 0001620463 atha:SeriesB1ConvertiblePreferredStockMember 2020-05-01 2020-06-30 0001620463 us-gaap:CommonStockMember us-gaap:IPOMember 2020-09-30 0001620463 atha:SharesIssuableUponExerciseOfOutstandingCommonStockOptionsAndVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember 2021-03-31 0001620463 atha:SharesIssuableUponExerciseOfOutstandingCommonStockOptionsAndVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember 2020-12-31 0001620463 atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember 2021-03-31 0001620463 atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember 2020-12-31 0001620463 atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember 2021-03-31 0001620463 atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember 2020-12-31 0001620463 atha:TwoThousandAndTwentyEquityIncentivePlanMember 2021-01-01 2021-03-31 0001620463 atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-03-31 0001620463 atha:TwoThousandAndTwentyEquityIncentivePlanMember 2021-03-31 0001620463 atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember 2021-03-31 0001620463 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001620463 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001620463 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001620463 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001620463 atha:EmployeesAndDirectorsMember 2021-01-01 2021-03-31 0001620463 atha:EmployeesAndDirectorsMember 2020-01-01 2020-03-31 0001620463 atha:AdvisorsMember 2021-01-01 2021-03-31 0001620463 atha:AdvisorsMember 2020-01-01 2020-03-31 0001620463 2020-01-01 2020-12-31 0001620463 atha:ExercisePriceOneMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceTwoMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceThreeMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceFourMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceFiveMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceSixMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceSevenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceEightMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceNineMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceTenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceElevenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceTwelveMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceThirteenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceFourteenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceFifteenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceSixteenMember 2021-01-01 2021-03-31 0001620463 atha:ExercisePriceOneMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceTwoMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceFourMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceFiveMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceSixMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceSevenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceEightMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceNineMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceTenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceElevenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceTwelveMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceThirteenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceFourteenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceFifteenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceSixteenMember atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:EmployeesAndDirectorsMember 2021-03-31 0001620463 atha:ExercisePriceOneMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:ExercisePriceThreeMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:ExercisePriceFourMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:ExercisePriceFiveMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:ExercisePriceSevenMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:ExercisePriceNineMember atha:NonEmployeesMember 2021-03-31 0001620463 atha:NonEmployeesMember 2021-03-31 0001620463 us-gaap:RestrictedStockMember atha:NonEmployeesMember 2021-03-31 0001620463 us-gaap:RestrictedStockMember atha:NonEmployeesMember 2020-12-31 0001620463 us-gaap:RestrictedStockMember 2020-12-31 0001620463 us-gaap:RestrictedStockMember 2021-03-31 0001620463 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001620463 atha:ConvertiblePreferredStockOnConvertedBasisMember 2020-01-01 2020-03-31 0001620463 atha:NonVestedRestrictedStockAwardsMember 2021-01-01 2021-03-31 0001620463 atha:NonVestedRestrictedStockAwardsMember 2020-01-01 2020-03-31 0001620463 atha:NonVestedRestrictedStockUnitsMember 2021-01-01 2021-03-31 0001620463 atha:StockOptionsToPurchaseCommonStockMember 2021-01-01 2021-03-31 0001620463 atha:StockOptionsToPurchaseCommonStockMember 2020-01-01 2020-03-31 0001620463 atha:EmployeeStockPurchasePlanMember 2021-01-01 2021-03-31 0001620463 atha:CommonStockWarrantsMember 2020-01-01 2020-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2021

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____ to ____

Commission File Number: 001-39503

 

Athira Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

45-3368487

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

 

18706 North Creek Parkway, Suite 104

Bothell, Washington 98011

(Address of principal executive offices)

(425) 620-8501

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

ATHA

The Nasdaq Stock Market LLC

 

 

(The Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 10, 2021 there were 37,222,666 shares of registrant’s common stock, $0.0001 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

5

Item 1.

Financial Statements (Unaudited)

5

 

Condensed Consolidated Balance Sheets

5

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

6

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity

7

 

Condensed Consolidated Statements of Cash Flows

8

 

Notes to Unaudited Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

35

Item 4.

Controls and Procedures

35

PART II.

OTHER INFORMATION

36

Item 1.

Legal Proceedings

36

Item 1A.

Risk Factors

36

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

85

Item 3.

Defaults Upon Senior Securities

85

Item 4.

Mine Safety Disclosures

85

Item 5.

Other Information

85

Item 6.

Exhibits

86

Signatures

87

 

This report includes our trademarks and registered trademarks, including Athira, Athira Pharma, the Athira logo, and other trademarks or service marks of Athira. Each other trademark, trade name or service mark appearing in this report belongs to its holder.

 

2


 

SUMMARY RISK FACTORS

 

Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned “Risk Factors.” The following is a summary of the principal risks we face:

 

We are a late clinical-stage biopharmaceutical company with a limited operating history.

 

Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives.

 

Our development of ATH-1017 may never lead to a marketable product.

 

Our approach to targeting brain growth factors through the use of small molecules is based on a novel therapeutic approach, which exposes us to unforeseen risks. We have limited data from our Phase 1a and 1b clinical trials, including only 11 patients with mild to moderate Alzheimer’s disease, and we cannot be certain that future trials will yield similar data. In addition, our use of electroencephalogram methods to gather data requires placement of electrodes on a subject’s scalp and, if not properly placed, we may be unable to obtain the data sought or data obtained may be unreliable.

 

We have concentrated our research and development efforts on the treatment of central nervous system and peripheral degenerative disorders, a field that has seen very limited success in product development.

 

Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials across multiple clinical trial sites. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all.

 

If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.

 

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

 

The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our nonclinical studies and clinical trials.

 

We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.

 

We will require substantial additional funding to finance our operations, complete the development and commercialization of ATH-1017, and evaluate other and future product candidates. If we are unable to raise this funding when needed, we may be forced to delay, reduce, or eliminate our product development programs or other operations.

 

The regulatory approval processes of the U.S. Food and Drug Administration and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.

 

We plan to rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.

3


 

 

Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

 

We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.

 

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

 

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.

 

The market price of our common stock may be volatile, which could result in substantial losses for investors.

4


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Athira Pharma, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

March 31,

2021

 

 

December 31,

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

127,823

 

 

$

60,625

 

Short-term investments

 

 

176,367

 

 

 

124,057

 

Unbilled grant receivable

 

 

2,906

 

 

 

1,300

 

Prepaid expenses and other current assets

 

 

4,472

 

 

 

6,355

 

Total current assets

 

 

311,568

 

 

 

192,337

 

Property and equipment, net

 

 

2,898

 

 

 

2,649

 

Operating lease right-of-use asset

 

 

1,426

 

 

 

936

 

Long-term investments

 

 

53,467

 

 

 

83,509

 

Other long-term assets

 

 

55

 

 

 

132

 

Total assets

 

$

369,414

 

 

$

279,563

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,687

 

 

$

1,158

 

Accrued liabilities

 

 

2,610

 

 

 

3,123

 

Current operating lease liability

 

 

200

 

 

 

124

 

Total current liabilities

 

 

4,497

 

 

 

4,405

 

Operating lease liability, less current portion

 

 

1,700

 

 

 

876

 

Total liabilities

 

 

6,197

 

 

 

5,281

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value; 900,000,000 shares

   authorized at March 31, 2021 and December 31, 2020;

   37,150,311 and 32,485,784 shares issued and

   outstanding at March 31, 2021 and December 31, 2020,

   respectively

 

 

4

 

 

 

3

 

Additional paid-in capital

 

 

413,093

 

 

 

315,288

 

Accumulated other comprehensive income

 

 

28

 

 

 

33

 

Accumulated deficit

 

 

(49,908

)

 

 

(41,042

)

Total stockholders' equity

 

 

363,217

 

 

 

274,282

 

Total liabilities and stockholders'

   equity

 

$

369,414

 

 

$

279,563

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

Athira Pharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

7,445

 

 

$

592

 

General and administrative

 

 

3,336

 

 

 

675

 

Total operating expenses

 

 

10,781

 

 

 

1,267

 

Loss from operations

 

 

(10,781

)

 

 

(1,267

)

Grant income

 

 

1,831

 

 

 

22

 

Other income (expense), net

 

 

84

 

 

 

(560

)

Net loss

 

$

(8,866

)

 

$

(1,805

)

Unrealized (loss) on available-for-sale securities

 

 

(5

)

 

 

 

Comprehensive loss attributable to common stockholders

 

$

(8,871

)

 

$

(1,805

)

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(0.25

)

 

$

(0.48

)

Weighted-average shares used in computing net loss per

   share attributable to common stockholders, basic and

   diluted

 

 

35,775,454

 

 

 

3,747,356

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

Athira Pharma, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ (Deficit) Equity

For the Three Months Ended March 31, 2021 and 2020

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Total

 

 

 

Convertible

Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Other

Comprehensive

 

 

Accumulated

 

 

Stockholders’

(Deficit)

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of January 1, 2020

 

 

2,617,386

 

 

$

17,051

 

 

 

 

3,641,449

 

 

$

 

 

$

1,364

 

 

$

 

 

$

(21,087

)

 

$

(19,723

)

Issuance of common stock upon

   exercise of common stock options

 

 

 

 

 

 

 

 

 

220,043

 

 

 

 

 

 

176

 

 

 

 

 

 

 

 

 

176

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

58

 

 

 

 

 

 

 

 

 

58

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,805

)

 

 

(1,805

)

Balance as of March 31, 2020

 

 

2,617,386

 

 

$

17,051

 

 

 

 

3,861,492

 

 

$

 

 

$

1,598

 

 

$

 

 

$

(22,892

)

 

$

(21,294

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Total

 

 

 

Convertible

Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Other

Comprehensive

 

 

Accumulated

 

 

Stockholders’

(Deficit)

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of January 1, 2021

 

 

 

 

$

 

 

 

 

32,485,784

 

 

$

3

 

 

$

315,288

 

 

$

33

 

 

$

(41,042

)

 

$

274,282

 

Issuance of common stock upon

   exercise of common stock options

   and vesting of restricted stock units

 

 

 

 

 

 

 

 

 

64,527

 

 

 

 

 

 

70

 

 

 

 

 

 

 

 

 

70

 

Proceeds from follow-on public offering,

   net of underwriters' discounts and

   commissions and issuance costs

 

 

 

 

 

 

 

 

 

4,600,000

 

 

 

1

 

 

 

96,761

 

 

 

 

 

 

 

 

 

96,762

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

974

 

 

 

 

 

 

 

 

 

974

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5

)

 

 

 

 

 

(5

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,866

)

 

 

(8,866

)

Balance as of March 31, 2021

 

 

 

 

$

 

 

 

 

37,150,311

 

 

$

4

 

 

$

413,093

 

 

$

28

 

 

$

(49,908

)

 

$

363,217

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7


 

Athira Pharma, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(8,866

)

 

$

(1,805

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

974

 

 

 

58

 

Depreciation expense

 

 

112

 

 

 

 

Change in fair value of derivative liability

 

 

 

 

 

445

 

Change in fair value of grant liability

 

 

 

 

 

(97

)

Accretion of discounts on convertible notes

 

 

 

 

 

172

 

Non-cash interest expense

 

 

 

 

 

46

 

Amortization of premiums and accretion of discounts on

   available-for-sale securities, net

 

 

131

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Unbilled grant receivables, prepaid expenses and other

   current assets

 

 

308

 

 

 

(57

)

Accounts payable and accrued expenses

 

 

(374

)

 

 

63

 

Operating lease liability

 

 

410

 

 

 

 

Net cash (used in) operating activities

 

 

(7,305

)

 

 

(1,175

)

Investing activities

 

 

 

 

 

 

 

 

Purchases of available-for-sale securities

 

 

(93,143

)

 

 

 

Maturities of available-for-sale securities

 

 

70,739

 

 

 

 

Purchases of property and equipment

 

 

(304

)

 

 

 

Principal payments received on stockholder note receivable

 

 

 

 

 

1

 

Net cash (used in) provided by investing activities

 

 

(22,708

)

 

 

1

 

Financing activities

 

 

 

 

 

 

 

 

Proceeds from exercise of common stock options

 

 

39

 

 

 

176

 

Proceeds from follow-on public offering, net of issuance costs

 

 

97,172

 

 

 

 

Proceeds from issuance of convertible notes, including derivative, net of

   issuance costs

 

 

 

 

 

1,664

 

Net cash provided by financing activities

 

 

97,211

 

 

 

1,840

 

Net increase (decrease) in cash and cash equivalents

 

 

67,198

 

 

 

666

 

Cash and cash equivalents, beginning of period

 

 

60,625

 

 

 

2,056

 

Cash and cash equivalents, end of period

 

$

127,823

 

 

$

2,722

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Purchases of property and equipment included in accounts payable and

   accrued liabilities

 

$

57

 

 

$

 

Right-of-use asset obtained in exchange for new operating lease liability

 

$

518

 

 

$

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

8


 

ATHIRA PHARMA, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Description of Business

Organization

Athira Pharma, Inc. (the “Company”) was incorporated as M3 Biotechnology, Inc. in the state of Washington on March 31, 2011 and reincorporated in the state of Delaware on October 27, 2015. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Seattle and Bothell Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.

Follow-on Public Offering

In January 2021, the Company completed a follow-on public offering of its common stock. As part of the follow-on offering, the Company issued and sold 4,000,000 shares of its common stock at a public offering price of $22.50 per share. The Company received net proceeds of approximately $84.1 million from the follow-on offering, after deducting underwriting discounts and commissions and offering costs. In February 2021, the Company sold an additional 600,000 shares of common stock to the underwriters of the follow-on public offering upon full exercise of the underwriters’ option to purchase additional shares at the follow-on public offering price of $22.50 per share, less underwriting discounts and commissions and offering costs resulting in net proceeds to the Company of approximately $12.7 million.

Liquidity and Capital Resources

Since the Company’s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company’s inception through March 31, 2021, it has raised aggregate net cash proceeds of $407.4 million primarily from the issuance of its common stock, convertible preferred stock, common stock warrants, and convertible notes. As of March 31, 2021, the Company had $357.7 million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company’s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company’s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

Based upon the Company’s current operating plan, it estimates that its $357.7 million of cash, cash equivalents, and investments at March 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this Quarterly Report on Form 10-Q.

 

2. Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). During the third quarter of 2020, the Company incorporated Athira Pharma Australia PTY LTD in Australia and since its creation, the Australian subsidiary’s financial position and results of operations are consolidated in the accompanying consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying unaudited condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of convertible preferred stock and stockholders’ deficit for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited

9


 

annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2020 included in its Annual Report on Form 10-K filed with the SEC on March 25, 2021.

Fair Value Measurements

The carrying amounts of certain financial instruments, including cash, cash equivalents, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts. The fair values of the grant liability to Washington Life Sciences Discovery Fund (“LSDF”), currently managed by the Washington State Department of Commerce, the derivative liability, and the convertible preferred stock warrant liability were estimated using level 3 unobservable inputs.

Convertible Preferred Stock Warrant Liability

Freestanding warrants to purchase shares of the Company’s convertible preferred stock were accounted for as liabilities at fair value, because the shares underlying the warrants contained contingent redemption features outside the control of the Company. Warrants classified as liabilities are recorded on the Company’s balance sheets at their fair value on the date of issuance and remeasured to fair value on each subsequent reporting period, with the changes in fair value recognized as a component of other income (expense), net in the accompanying statements of operations. The Company adjusted the liability for the final change in the fair value of these warrants immediately preceding their automatic exercise in connection with the Company’s IPO. Subsequent to the Company’s IPO, the corresponding liability was reclassified to additional paid in capital.

Grant Income

Grant income in the accompanying statements of operations consisted of the following for the three-month periods ended (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Alzheimer's Association Part the Cloud Research Grant

 

$

 

 

$

22

 

National Institutes of Health Grant

 

 

1,831

 

 

 

 

Total grant income

 

$

1,831

 

 

$

22

 

 

Amounts recorded in the accompanying balance sheets as receivables from these granting agencies were as follows (in thousands):

 

 

 

March 31,

2021

 

 

December 31,

2020

 

Alzheimer's Association Part the Cloud Research

   Grant

 

$

 

 

$

224

 

National Institutes of Health Grant

 

 

2,906

 

 

 

1,076

 

Total grant income

 

$

2,906

 

 

$

1,300

 

 

In January 2019, the Alzheimer’s Association awarded the Company a $1.0 million Part the Cloud research grant.  Grant proceeds must be used to advance the Company’s ATH-1017 product candidate in the Alzheimer’s disease setting.  Reporting of expenses incurred supported by the grant as well as research updates are sent to the Alzheimer’s Association semi-annually. Under the terms of the agreement, the Company received $776,000 in 2019 and received the remaining $224,000 in March 2021 after having completed certain development milestones in October 2020. The Company recognized income related to the Part the Cloud research grant as qualifying expenses under the grant agreement were incurred.

10


 

In December 2020, the Company accepted a grant from the National Institute on Aging (“NIA”) of the National Institutes of Health (“NIH”) to support its ACT-AD Phase 2 clinical trial for ATH-1017, the Company’s lead therapeutic candidate being developed for the treatment of individual with mild-to-moderate Alzheimer’s disease. Under the terms of the agreement, the Company may potentially receive $7.8 million with the potential for an additional $7.4 million, up to an aggregate of $15.2 million. The Company recognizes income related to the NIH grant as qualifying expenses under the grant agreement are incurred.

 

Short-term and Long-term Investments

The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.

The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company’s proprietary drug discovery platform (“ATH platform”). The Company’s drug discovery efforts and the development of its product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company’s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.

Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

11


 

Leases

The Company adopted Accounting Standards Codification (“ASC”) Topic 842 - Leases, on July 1, 2020, effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company’s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company’s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company’s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date, discussed in more detail below.

The Company’s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company’s lease agreements do not contain residual value guarantees or covenants.

The Company has made a policy election regarding its real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. The Company’s lease includes variable nonlease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.

Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company’s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.

Stock-based Compensation

The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.

The Company records compensation expense for stock option grants subject to performance-based milestone vesting using the accelerated attribution method over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

The Company adopted Accounting Standards Update (“ASU”) 2018-07 as of January 1, 2020. As a result, stock-based payments issued to non-employees prior to January 1, 2020 have been recorded at their fair values as of the transition date and are no longer subject to periodic adjustments as the underlying equity instruments vest. Any remaining compensation expense is recognized over the remaining vesting term on a straight-line basis, which reflects the service period, based on the fair value as of January 1, 2020.

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.

12


 

Segments

The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company’s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

 

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The ASU will become effective beginning January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impacts of the ASU on its financial condition, results of operations, cash flows and financial statement disclosures.

Although there were several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of these have had or will have material impact on its condensed consolidated financial statements.

 

3. Fair Value

The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:

Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2—Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3—Inputs are generally unobservable and reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.

The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

13


 

The following tables reflect the Company’s financial asset balances measured on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):

 

 

 

March 31, 2021

 

 

 

Level

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market fund

 

1

 

$

54,549

 

 

$

 

 

$

 

 

$

54,549

 

Commercial paper

 

2

 

 

63,829

 

 

 

 

 

 

(3

)

 

 

63,826

 

Total cash equivalents

 

 

 

$

118,378

 

 

$

 

 

$

(3

)

 

$

118,375

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

2

 

 

116,581

 

 

 

 

 

 

(15

)

 

 

116,566

 

U.S. government debt and agency

   securities

 

2

 

 

49,258

 

 

 

21

 

 

 

 

 

 

49,279

 

Corporate bonds

 

2

 

 

10,528

 

 

 

 

 

 

(6

)

 

 

10,522

 

Total short-term investments

 

 

 

$

176,367

 

 

$

21

 

 

$

(21

)

 

$

176,367

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government debt and agency

   securities

 

2

 

 

53,436

 

 

 

31

 

 

 

 

 

 

53,467

 

Total long-term investments

 

 

 

$

53,436

 

 

$

31

 

 

$

 

 

$

53,467

 

 

 

 

December 31, 2020

 

 

 

Level

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market fund

 

1

 

$

5

 

 

$

 

 

$

 

 

$

5

 

Commercial paper

 

2

 

 

44,318

 

 

 

 

 

 

(2

)

 

 

44,316

 

U.S. government debt and agency

   securities

 

2

 

 

4,999

 

 

 

 

 

 

 

 

 

4,999

 

U.S. treasury bills

 

2

 

 

4,450

 

 

 

 

 

 

 

 

 

4,450

 

Total cash equivalents

 

 

 

$

53,772

 

 

$

 

 

$

(2

)

 

$

53,770

 

Short-term investments: